2022
DOI: 10.1016/j.wneu.2021.12.091
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy and Safety of Bevacizumab Combined with Other Therapeutic Regimens for Treatment of Recurrent Glioblastoma: A Network Meta-analysis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
6
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 6 publications
(6 citation statements)
references
References 36 publications
0
6
0
Order By: Relevance
“…It should be underlined that combined treatments appear of great interest in the development of anticancer approaches [ 7 , 8 , 9 , 10 , 11 , 12 ], since they are expected to obtain the same biological or therapeutic effect using lower concentrations of two or more drugs, thereby limiting side effects [ 58 ]. Importantly, combined therapy might be of great importance in the management of Glioblastoma (GBM), a lethal malignant tumor needing novel therapeutic options.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…It should be underlined that combined treatments appear of great interest in the development of anticancer approaches [ 7 , 8 , 9 , 10 , 11 , 12 ], since they are expected to obtain the same biological or therapeutic effect using lower concentrations of two or more drugs, thereby limiting side effects [ 58 ]. Importantly, combined therapy might be of great importance in the management of Glioblastoma (GBM), a lethal malignant tumor needing novel therapeutic options.…”
Section: Discussionmentioning
confidence: 99%
“…Combined treatment might be of great interest in order to develop effective therapeutic protocols for glioblastoma [ 7 , 8 , 9 , 10 , 11 , 12 ]. In this respect, we have recently reported a possible combined therapeutic approach for GBM based on the use of microRNA inhibitors and anti-GBM molecules.…”
Section: Introductionmentioning
confidence: 99%
“…This drug is approved for the treatment of recurrent GB [ 123 ] and extends progression‐free survival when combined with standard‐of‐care radiochemotherapy. [ 86b ] However, a recent meta‐analysis study [ 124 ] indicated no significant increase in overall survival, except for combined therapy with other drugs and radiation. At the same time, many of the tested drug combinations that included BEV and improved overall survival had increased toxicity.…”
Section: The Current State Of Combination Drug Testing In 3d In Vitro...mentioning
confidence: 99%
“…The comparison of the outcomes in terms of 6‐months overall and progression‐free survival and safety profiles across multiple relevant clinical reports on combination drug treatment of GB using BEV revealed that the best results were achieved by combining BEV with lomustine or Rindopepimut, while in combination with TMZ, BEV allowed getting moderate improvement of the clinical outcome. [ 124 ]…”
Section: The Current State Of Combination Drug Testing In 3d In Vitro...mentioning
confidence: 99%
See 1 more Smart Citation